Cardiovasc Prev Pharmacother.  2022 Jul;4(3):95-98. 10.36011/cpp.2022.4.e14.

Cardiovascular diseases in HIV patients

• Chang HH

• KMID: 2532274
• DOI: http://doi.org/10.36011/cpp.2022.4.e14

Abstract

New and more effective antiretroviral therapy regimens have increased viral suppression and improved immune function recovery, leading to the extension of the lifespan of people living with HIV (PLWH). The extended lifespan of PLWH has recently been reported as a significant factor associated with diabetes mellitus, dyslipidemia, and long-term metabolic consequences, such as cardiovascular diseases. Therefore, this article briefly reviews the epidemiology and risk factors of cardiovascular diseases, including dyslipidemia and diabetes mellitus, in PLWH.

Keyword

HIV; Cardiovascular diseases; Antiretroviral therapy

Reference

1. Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, et al. HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers. 2020; 6:48.

2. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009; 2:231–7.

3. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120:1640–5.

4. Nguyen KA, Peer N, Mills EJ, Kengne AP. A meta-analysis of the metabolic syndrome prevalence in the global HIV-infected population. PLoS One. 2016; 11:e0150970.

5. Bailin SS, Gabriel CL, Wanjalla CN, Koethe JR. Obesity and weight gain in persons with HIV. Curr HIV/AIDS Rep. 2020; 17:138–50.

6. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992; 74:1045–52.

7. El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 2005; 6:114–21.

8. Funderburg NT, Mehta NN. Lipid abnormalities and inflammation in HIV inflection. Curr HIV/AIDS Rep. 2016; 13:218–25.

9. Bijker R, Choi JY, Ditangco R, Kiertiburanakul S, Lee MP, Siwamogsatham S, et al. Cardiovascular disease and cardiovascular disease risk in HIV-positive populations in the Asian region. Open AIDS J. 2017; 11:52–66.

10. Lo J. Dyslipidemia and lipid management in HIV-infected patients. Curr Opin Endocrinol Diabetes Obes. 2011; 18:144–7.

11. Crane HM, Grunfeld C, Willig JH, Mugavero MJ, Van Rompaey S, Moore R, et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS. 2011; 25:185–95.

12. Valantin MA, Bittar R, de Truchis P, Bollens D, Slama L, Giral P, et al. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. J Antimicrob Chemother. 2010; 65:556–61.

13. Plum PE, Maes N, Sauvage AS, Frippiat F, Meuris C, Uurlings F, et al. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. BMC Infect Dis. 2021; 21:910.

14. Lagoutte-Renosi J, Flammang M, Chirouze C, Beck-Wirth G, Bozon F, Brunel AS, et al. Real-life impact on lipid profile of a switch from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected patients. Curr HIV Res. 2021; 19:84–9.

15. The RESPOND Study Group. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. AIDS. 2021; 35:869–82.

16. Saumoy M, Sanchez-Quesada JL, Ordonez-Llanos J, Podzamczer D. Do all integrase strand transfer inhibitors have the same lipid profile? Review of randomised controlled trials in naive and switch scenarios in HIV-infected patients. J Clin Med. 2021; 10:3456.

17. Achhra AC, Sabin C, Ryom L, Hatleberg C, Antonella dʼAminio M, de Wit S, et al. Body mass index and the risk of serious non-AIDS events and all-cause mortality in treated HIV-positive individuals: D:A:D cohort analysis. J Acquir Immune Defic Syndr. 2018; 78:579–88.

18. Nansseu JR, Bigna JJ, Kaze AD, Noubiap JJ. Incidence and risk factors for prediabetes and diabetes mellitus among HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Epidemiology. 2018; 29:431–41.

19. Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, et al. HIV infection and the risk of diabetes mellitus. AIDS. 2009; 23:1227–34.

20. Duncan AD, Goff LM, Peters BS. Type 2 diabetes prevalence and its risk factors in HIV: a cross-sectional study. PLoS One. 2018; 13:e0194199.

21. Putcharoen O, Wattanachanya L, Sophonphan J, Siwamogsatham S, Sapsirisavat V, Gatechompol S, et al. New-onset diabetes in HIV-treated adults: predictors, long-term renal and cardiovascular outcomes. AIDS. 2017; 31:1535–43.

22. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005; 165:1179–84.

23. Herrin M, Tate JP, Akgun KM, Butt AA, Crothers K, Freiberg MS, et al. Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals. J Acquir Immune Defic Syndr. 2016; 73:228–36.

24. Kim JH, Noh J, Kim W, Seong H, Kim JH, Lee WJ, et al. Trends of age-related non-communicable diseases in people living with HIV and comparison with uninfected controls: a nationwide population-based study in South Korea. HIV Med. 2021; 22:824–33.

25. Shah AS, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation. 2018; 138:1100–12.

26. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007; 92:2506–12.

27. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009; 23:1059–67.

28. Nordell AD, McKenna M, Borges AH, Duprez D, Neuhaus J, Neaton JD, et al. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc. 2014; 3:e000844.

29. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d’Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy: results from the DAD study. AIDS. 2003; 17:1179–93.

30. DAD Study Group, Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte Ad, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007; 356:1723–35.

31. D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008; 371:1417–26.